Login to Your Account



Financings NEWS

Bridgebio Pharma Inc. disclosed the second company in its growing portfolio of subsidiaries targeting genetic diseases, endowing Eidos Therapeutics with $27 million to advance its lead compound, AG-10, for the treatment of transthyretin (TTR) amyloidosis.

Arsanis Inc., an infectious disease specialist developing a targeted monoclonal antibody to prevent Staphylococcus aureus pneumonia, has closed on a $45.5 million series D financing that will help it complete a phase II trial of candidate ASN-100.

LONDON – Synpromics Ltd has raised £5.2 million in a series B round to advance the development and commercialization of its synthetic promoter technology for controlling and directing gene expression.

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: